SEC Company Response from Viking Therapeutics, Inc. (VKTX) (CIK 0001607678) (VKTX) — Sep 15, 2014
Viking Therapeutics, Inc. (VKTX) (CIK 0001607678)
Date: Sept. 15, 2014 · CIK: 0001607678 · Accession: 0001193125-14-341745
AI Filing Summary & Sentiment
File numbers found in text: 333-197182
Letter
Acceleration (Company)
11119 North Torrey Pines Road, Suite 50
San Diego, CA 92037
September 15, 2014
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Johnny Gharib, Esq.
Re: Viking Therapeutics, Inc.
Registration Statement on Form S-1
Registration No. 333-197182
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Viking Therapeutics, Inc. (the “Registrant”) hereby respectfully requests that the effectiveness of the Registration Statement on Form S-1 (File No. 333-197182) of the Registrant (as amended, the “Registration Statement”) be accelerated so that it will be declared effective at 4:00 p.m., Eastern Daylight Time, on September 17, 2014 or as soon thereafter as may be practicable.
The Registrant hereby confirms that it is aware of its responsibilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, as they relate to the proposed offering of the securities specified in the Registration Statement. The Registrant hereby acknowledges that:
•
should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, Paul Hastings LLP, by calling Jeffrey T. Hartlin at (650) 320-1804. The Company hereby authorizes Mr. Hartlin to orally modify or withdraw this request for acceleration.
Please also provide a copy of the Commission’s order declaring the Registration Statement effective to Mr. Hartlin via email to jeffhartlin@paulhastings.com or facsimile to (650) 320-1904 and via mail c/o Paul Hastings LLP, 1117 S. California Avenue, Palo Alto, CA 94304.
Sincerely,
VIKING THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
Acceleration (Company)
11119 North Torrey Pines Road, Suite 50
San Diego, CA 92037
September 15, 2014
VIA EDGAR
United States Securities and Exchange
Commission
Division of Corporation Finance
100 F Street,
N.E.
Washington, D.C. 20549
Attention: Johnny Gharib, Esq.
Re:
Viking Therapeutics, Inc.
Registration Statement on Form S-1
Registration No. 333-197182
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Viking Therapeutics, Inc. (the “Registrant”)
hereby respectfully requests that the effectiveness of the Registration Statement on Form S-1 (File No. 333-197182) of the Registrant (as amended, the “Registration Statement”) be accelerated so that it will be
declared effective at 4:00 p.m., Eastern Daylight Time, on September 17, 2014 or as soon thereafter as may be practicable.
The
Registrant hereby confirms that it is aware of its responsibilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, as they relate to the proposed offering of the securities specified in the
Registration Statement. The Registrant hereby acknowledges that:
•
should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the
Commission from taking any action with respect to the Registration Statement;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and
accuracy of the disclosure in the filing; and
•
the Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The undersigned respectfully requests that it be notified of the effectiveness of the
Registration Statement by telephone call to our counsel, Paul Hastings LLP, by calling Jeffrey T. Hartlin at (650) 320-1804. The Company hereby authorizes Mr. Hartlin to orally modify or withdraw this request for acceleration.
Please also provide a copy of the Commission’s order declaring the Registration Statement effective to Mr. Hartlin via email to
jeffhartlin@paulhastings.com or facsimile to (650) 320-1904 and via mail c/o Paul Hastings LLP, 1117 S. California Avenue, Palo Alto, CA 94304.
Sincerely,
VIKING THERAPEUTICS, INC.
By:
/s/ Brian Lian, Ph.D.
Brian Lian, Ph.D.
President and Chief Executive Officer
cc:
Jeffrey T. Hartlin, Esq. (Paul Hastings LLP)